Exosome Diagnostics, Amgen Collaborate
News Oct 04, 2016
Exosome Diagnostics Inc has entered into an agreement with Amgen to evaluate the potential to advance drug development with Exosome’s proprietary liquid biopsy diagnostics technology and platform. Under the terms of the agreement, the companies will collaborate to identify a potential liquid biopsy diagnostic. Financial terms of the agreement were not disclosed.
Liquid biopsies are effective in advancing therapeutics because of their distinct advantage over tissue biopsies. A significant advantage is that they are less invasive, resulting in fewer complications and risks to the patient during sample collection. Liquid biopsies enable easier sample collection and may help facilitate patient enrollment into trials.
“We are excited to initiate this agreement with Amgen on developing technology that may advance the use of liquid biopsy tests in clinical development,” stated Mario Morken, Head of Business Development for Exosome Diagnostics. “Exosome Diagnostic’s technology and expertise allows for the development of highly sensitive liquid biopsy assays.”
“The strategy and positioning of the company since the beginning of 2016 is garnering significant results, and we look forward to expounding upon these successes,” stated John Boyce, President and CEO of Exosome Diagnostics.
Shire, Microsoft and EURORDIS Form Global Commission to Accelerate Rare Disease DiagnosisNews
The alliance aims to shorten the often multi-year journey that patients and families endure before being diagnosed with a rare disease.READ MORE
Breast Cancer: How Advanced Imaging Technologies Will Help Avoid Unnecessary BiopsiesNews
Scientists have combined an advanced method of diffusion-weighted MR imaging with intelligent image analysis methods to detect malignant changes in tissues. This method may help avoid many control biopsies following suspicious findings from mammography screening.READ MORE
Liquid Biopsy Can Help Predict Outcomes in Metastatic Triple-Negative Breast CancerNews
A clinically relevant “liquid biopsy” test can be used to profile cancer genomes from blood and predict survival outcomes for patients with metastatic triple negative breast cancer.READ MORE